FibroGen Inc (FGEN)
0.304
-0.02
(-5.68%)
USD |
NASDAQ |
Nov 05, 16:00
0.304
0.00 (0.00%)
After-Hours: 18:59
FibroGen Enterprise Value: 6.090M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 6.090M |
| November 01, 2024 | 5.749M |
| October 31, 2024 | 3.992M |
| October 30, 2024 | 5.638M |
| October 29, 2024 | 4.474M |
| October 28, 2024 | 3.731M |
| October 25, 2024 | 4.654M |
| October 24, 2024 | 5.859M |
| October 23, 2024 | 5.859M |
| October 22, 2024 | 8.901M |
| October 21, 2024 | 11.33M |
| October 18, 2024 | 13.04M |
| October 17, 2024 | 13.39M |
| October 16, 2024 | 11.45M |
| October 15, 2024 | 9.313M |
| October 14, 2024 | 8.178M |
| October 11, 2024 | 9.604M |
| October 10, 2024 | 7.566M |
| October 09, 2024 | 6.632M |
| October 08, 2024 | 6.703M |
| October 07, 2024 | 8.128M |
| October 04, 2024 | 10.55M |
| October 03, 2024 | 13.78M |
| October 02, 2024 | 13.88M |
| October 01, 2024 | 13.09M |
| Date | Value |
|---|---|
| September 30, 2024 | 13.83M |
| September 27, 2024 | 14.53M |
| September 26, 2024 | 13.05M |
| September 25, 2024 | 11.18M |
| September 24, 2024 | 12.25M |
| September 23, 2024 | 11.09M |
| September 20, 2024 | 14.75M |
| September 19, 2024 | 15.50M |
| September 18, 2024 | 15.90M |
| September 17, 2024 | 18.72M |
| September 16, 2024 | 19.13M |
| September 13, 2024 | 20.92M |
| September 12, 2024 | 16.23M |
| September 11, 2024 | 13.53M |
| September 10, 2024 | 13.89M |
| September 09, 2024 | 13.37M |
| September 06, 2024 | 12.89M |
| September 05, 2024 | 16.42M |
| September 04, 2024 | 13.85M |
| September 03, 2024 | 7.064M |
| August 30, 2024 | 10.44M |
| August 29, 2024 | 10.99M |
| August 28, 2024 | 10.40M |
| August 27, 2024 | 12.40M |
| August 26, 2024 | 13.39M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-145.12M
Minimum
Sep 22 2023
4.434B
Maximum
Feb 12 2021
1.326B
Average
938.27M
Median
Aug 10 2022
Enterprise Value Benchmarks
| Merck & Co Inc | 284.72B |
| Biomarin Pharmaceutical Inc | 12.24B |
| Arbutus Biopharma Corp | 586.71M |
| GlycoMimetics Inc | 4.052M |
| Cidara Therapeutics Inc | -72.66M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -15.54M |
| Revenue (Quarterly) | 50.64M |
| Total Expenses (Quarterly) | 61.56M |
| EPS Diluted (Quarterly) | -0.16 |
| Gross Profit Margin (Quarterly) | 89.78% |
| Profit Margin (Quarterly) | -30.69% |
| Earnings Yield | -562.5% |
| Normalized Earnings Yield | -529.16 |